Glimmat 2 Tablet is a combination oral antidiabetic medication containing Glimepiride 2mg and Metformin 500mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, stimulates pancreatic beta cells to enhance insulin secretion, thereby improving glycemic control. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production and increasing peripheral insulin sensitivity, contributing to improved glucose uptake and utilization. The synergistic action of these two agents addresses both insulin deficiency and insulin resistance, making Glimmat 2 effective in patients inadequately controlled by diet, exercise, and monotherapy. It is typically prescribed as part of a comprehensive diabetes management plan including lifestyle modifications. Glimmat 2 should be used cautiously in patients with renal or hepatic impairment, cardiovascular disease, or conditions predisposing to hypoxia, as metformin carries a risk of lactic acidosis in such populations. Common adverse effects may include gastrointestinal disturbances such as nausea, vomiting, diarrhea, and hypoglycemia, primarily due to glimepiride. Regular monitoring of blood glucose levels, renal function, and adherence to dietary recommendations is essential to optimize therapeutic outcomes and minimize risks. Glimmat 2 Tablet should be taken as directed by a healthcare professional to ensure safe and effective diabetes management.